<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035434</url>
  </required_header>
  <id_info>
    <org_study_id>CRSP-ONC-001</org_study_id>
    <nct_id>NCT04035434</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)</brief_title>
  <official_title>A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CRISPR Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CRISPR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase 1 study evaluating the safety and efficacy of&#xD;
      CTX110 in subjects with relapsed or refractory B-cell malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study may enroll up to 143 subjects in total. CTX110 is a CD19-directed chimeric antigen&#xD;
      receptor (CAR) T cell immunotherapy comprised of allogeneic T cells prepared for the&#xD;
      treatment of B cell malignancies. The cells are from healthy adult volunteer donors that are&#xD;
      genetically modified ex vivo using CRISPR-Cas9 (clustered regularly interspaced short&#xD;
      palindromic repeats/ CRISPR-associated protein 9) gene editing components (single guide RNA&#xD;
      and Cas9 nuclease).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A (Dose Escalation), for all cohorts: Incidence of adverse events, defined as dose-limiting toxicities</measure>
    <time_frame>From CTX110 infusion up to 28 days post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (Cohort Expansion), for NHL: Objective response rate</measure>
    <time_frame>From CTX110 infusion up to 60 months post-infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From date of first objective response of CR/PR until date of disease progression or death due to any cause, assessed up to 60 months</time_frame>
    <description>Duration of Response (DOR) will only be reported for subjects who have had CR/PR events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Clinical Benefit (DOCB)</measure>
    <time_frame>From date of first objective response of CR/PR until the relapse or death that followed the last response, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From date of CTX110 infusion until date of disease progression or death due to any cause, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of CTX110 infusion until date of death due to any cause, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (for B cell ALL)</measure>
    <time_frame>From CTX110 infusion up to 60 months post-infusion</time_frame>
    <description>For B cell ALL, objective response rate (ORR) (complete remission + complete remission with incomplete blood count recovery [CRi]) will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">143</enrollment>
  <condition>B-cell Malignancy</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>B-cell Lymphoma</condition>
  <condition>Adult B Cell ALL</condition>
  <arm_group>
    <arm_group_label>CTX110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by IV infusion following lymphodepleting chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTX110</intervention_name>
    <description>CTX110 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components</description>
    <arm_group_label>CTX110</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. For NHL patients: Age ≥18 years. For B cell ALL patients: age ≥18 years to ≤70 years&#xD;
&#xD;
          2. Refractory or relapsed non-Hodgkin lymphoma, as evidenced by 2 or more lines of prior&#xD;
             therapy, or histologically confirmed B cell ALL, refractory or relapsed.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group performance status 0 or 1.&#xD;
&#xD;
          4. Adequate renal, liver, cardiac and pulmonary organ function&#xD;
&#xD;
          5. Female subjects of childbearing potential and male subjects must agree to use&#xD;
             acceptable method(s) of contraception from enrollment through at least 12 months after&#xD;
             CTX110 infusion.&#xD;
&#xD;
          6. Agree to participate in an additional long-term follow-up study after completion of&#xD;
             this study.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with any gene therapy or genetically modified cell therapy, including CAR T&#xD;
             cells.&#xD;
&#xD;
          2. For NHL patients: prior allogeneic HSCT. For B cell ALL patients: prior allogeneic&#xD;
             HSCT within 6 months, and/or any evidence of GvHD.&#xD;
&#xD;
          3. History of central nervous system (CNS) involvement by malignancy&#xD;
&#xD;
          4. History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia,&#xD;
             cerebellar disease, or any autoimmune disease with CNS involvement.&#xD;
&#xD;
          5. Presence of bacterial, viral, or fungal infection that is uncontrolled or requires IV&#xD;
             anti-infectives.&#xD;
&#xD;
          6. Active HIV, hepatitis B virus or hepatitis C virus infection.&#xD;
&#xD;
          7. Previous or concurrent malignancy, except basal cell or squamous cell skin carcinoma,&#xD;
             adequately resected and in situ carcinoma of cervix, or a previous malignancy that was&#xD;
             completely resected and has been in remission for ≥5 years.&#xD;
&#xD;
          8. For NHL patients: Use of systemic anti-tumor therapy or investigational agent within&#xD;
             14 days or 5 half-lives, whichever is longer, of enrollment. For B cell ALL patients:&#xD;
             Use of systemic antitumor therapy within 7 days of enrollment.&#xD;
&#xD;
          9. Primary immunodeficiency disorder or active autoimmune disease requiring steroids&#xD;
             and/or other immunosuppressive therapy.&#xD;
&#xD;
         10. Women who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewelina Morawa, MD</last_name>
    <role>Study Director</role>
    <affiliation>CRISPR Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>+1 (877) 214-4634</phone>
    <email>MedicalAffairs@crisprtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Immunotherapy Program</last_name>
      <email>HDFCCC.CIP@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph P McGuirk, DO</last_name>
      <phone>913-708-4032</phone>
      <email>jmcguirk@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeff Roesgen</last_name>
      <email>jroesgen@kumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Arnason, MD</last_name>
      <email>jarnason@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emma Logan, RN</last_name>
      <email>eklogan@bidmc.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Lyle, CRC-RN</last_name>
      <email>sonne054@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Insitute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Cameron</last_name>
      <email>heather.cameron@roswellpark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Maziarz, MD</last_name>
      <email>maziarzr@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kevin Christmas, PhD</last_name>
      <phone>503-494-6474</phone>
      <email>christmk@ohsu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patient Navigator</last_name>
      <phone>215-214-1515</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farrukh Awan, MD</last_name>
      <email>Farrukh.Awan@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Shaughnessy, MD</last_name>
      <email>Paul.Shaughnessy@MHShealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Sherri Shade, RN, CCRC</last_name>
      <phone>210-575-4238</phone>
      <email>Sherri.Shade@MHShealth.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Ho, MBBS</last_name>
      <phone>+61 2 95158036</phone>
      <email>christine.contacos@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Christine Contacos, PhD</last_name>
      <phone>+61 2 95153370</phone>
      <email>christine.contacos@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constantine Tam, MBBS, MD</last_name>
      <phone>+61 3 8559 7858</phone>
      <email>constantine.tam@petermac.org</email>
    </contact>
    <contact_backup>
      <last_name>Michael Dickinson, MBBS, MD</last_name>
      <phone>+61 3 8559 7858</phone>
      <email>michael.dickinson@petermac.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Kuruvilla, MD</last_name>
      <phone>416-946-2821</phone>
      <email>John.Kuruvilla@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Disha Prajapati</last_name>
      <phone>416-634-8737</phone>
      <email>disha.prajapati@uhn.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20148</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natascha von Huenerbein</last_name>
      <phone>+49 (0) 40 7410-23181</phone>
      <email>n.von-huenerbein@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Marion Heinzelmann</last_name>
      <phone>+49 (0) 40 7410 - 54188</phone>
      <email>mheinzel@uke.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR T</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>NHL</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

